Jump to content

Carlos Caldas: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
→‎References: has cats
Fix cite date error, added orphan tag
Line 1: Line 1:
{{Orphan|date=September 2019}}
⚫
{{Infobox scientist||

⚫
{{Infobox scientist
| name = Carlos Caldas
| name = Carlos Caldas
| honorific_suffix = {{post-nominals|country=GBR|FMedSci|size=100%}}
| honorific_suffix = {{post-nominals|country=GBR|FMedSci|size=100%}}
Line 31: Line 33:
| website = {{URL|www.cruk.cam.ac.uk/research-groups/caldas-group}}
| website = {{URL|www.cruk.cam.ac.uk/research-groups/caldas-group}}
}}
}}
'''Professor Carlos Caldas''' {{post-nominals|country=GBR|4=FMedSci}} is a clinician scientist and Senior Group Leader at the Cancer Research UK Cambridge Institute, [[University of Cambridge]]. He is the Chair of Cancer Medicine at the University of Cambridge, an Honorary Consultant Medical Oncologist at [[Addenbrooke's Hospital]] and Director of the Cambridge Breast Cancer Research Unit.<ref name=":0">{{Cite web|url=https://www.cuh.nhs.uk/cambridge-breast-unit/meet-team/oncologists/prof-c-caldas|title=Prof C Caldas {{!}} Cambridge University Hospitals|website=www.cuh.nhs.uk|access-date=2019-08-29}}</ref><ref>{{Cite web|url=https://www.oncology.cam.ac.uk/directory/c-caldas|title=Professor Carlos Caldas — Department of Oncology|[email protected]|website=www.oncology.cam.ac.uk|language=en|access-date=2019-08-29}}</ref>
'''Professor Carlos Caldas''' {{post-nominals|country=GBR|4=FMedSci}} is a clinician scientist and Senior Group Leader at the Cancer Research UK Cambridge Institute, [[University of Cambridge]]. He is the Chair of Cancer Medicine at the University of Cambridge, an Honorary Consultant Medical Oncologist at [[Addenbrooke's Hospital]] and Director of the Cambridge Breast Cancer Research Unit.<ref name=":0">{{Cite web|url=https://www.cuh.nhs.uk/cambridge-breast-unit/meet-team/oncologists/prof-c-caldas|title=Prof C Caldas {{!}} Cambridge University Hospitals|website=www.cuh.nhs.uk|access-date=2019-08-29}}</ref><ref>{{Cite web|url=https://www.oncology.cam.ac.uk/directory/c-caldas|title=Professor Carlos Caldas — Department of Oncology|[email protected]|website=www.oncology.cam.ac.uk|access-date=2019-08-29}}</ref>


== Education ==
== Education ==


Professor Carlos Caldas graduated from the [[University of Lisbon]] Medical School before training in Internal Medicine in [[University of Texas Southwestern Medical Center|University of Texas Southwestern]], Dallas and Medical Oncology at [[Johns Hopkins Hospital]], Baltimore. He then moved to the [[Institute of Cancer Research]], London to complete a research fellowship.<ref name=":0" />
Professor Carlos Caldas graduated from the [[University of Lisbon]] Medical School before training in Internal Medicine in [[University of Texas Southwestern Medical Center|University of Texas Southwestern]], Dallas and Medical Oncology at [[Johns Hopkins Hospital]], Baltimore. He then moved to the [[Institute of Cancer Research]], London to complete a research fellowship.<ref name=":0" />


== Research and Career ==
== Research and Career ==


Caldas' research focuses on the [[functional genomics]] of [[breast cancer]].<ref>{{Cite web|url=https://scholar.google.co.uk/citations?user=cWlqL14AAAAJ&hl=en|title=Carlos Caldas - Google Scholar Citations|website=scholar.google.co.uk|access-date=2019-08-29}}</ref><ref>{{Cite web|url=https://www.cruk.cam.ac.uk/research-groups/caldas-group|title=Caldas Group|website=Cancer Research UK Cambridge Institute|language=en-GB|access-date=2019-08-29}}</ref> Caldas led the METABRIC (Molecular Taxonomy of Breast Cancer International Consortium) study, analysing the [[genome]] and [[transcriptome]] of tumours from nearly 2,000 women and comparing this with long-term clinical information including survival, age and diagnosis. The METABRIC study concluded that breast cancer was at least ten different subtypes, characterised by distinct genomic drivers.<ref>{{Cite journal|last=Aparicio|first=Samuel|last2=Caldas|first2=Carlos|last3=Tavaré|first3=Simon|last4=Brenton|first4=James D.|last5=Børresen-Dale|first5=Anne-Lise|last6=Purushotham|first6=Arnie|last7=Ellis|first7=Ian|last8=Murphy|first8=Leigh|last9=Markowetz|first9=Florian|date=2012-06|title=The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups|url=https://www.nature.com/articles/nature10983|journal=Nature|language=en|volume=486|issue=7403|pages=346–352|doi=10.1038/nature10983|issn=1476-4687}}</ref><ref>{{Cite journal|last=Curtis|first=C.|last2=Shah|first2=S.|last3=Chin|first3=S.|last4=Turashvili|first4=G.|last5=Rueda|first5=O.|last6=Dunning|first6=M.|last7=Speed|first7=D.|last8=Lynch|first8=A.|last9=Samarajiwa|first9=S.|date=2012|title=The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups|url=https://scienceblog.cancerresearchuk.org/2012/04/18/increasing-the-resolution-on-breast-cancer-the-metabric-study/|journal=Nature|doi=10.1038/nature10983|issn=0028-0836}}</ref><ref>{{Cite news|url=https://www.bbc.com/news/health-17740690|title=Breast cancer map 'a key moment'|last=Gallagher|first=James|date=2012-04-18|access-date=2019-08-29|language=en-GB}}</ref> In 2019, the team published research showing the subtype a women's breast cancer is initially placed in could predict the likelyhood of the tumour returning or [[Metastasis|metastasising]] over the next 20 years.<ref>{{Cite journal|last=Curtis|first=Christina|last2=Caldas|first2=Carlos|last3=Aparicio|first3=Samuel|last4=Rueda|first4=Cristina|last5=Pharoah|first5=Paul D.|last6=Ellis|first6=Ian O.|last7=Purushotham|first7=Arnie|last8=Murphy|first8=Leigh|last9=Green|first9=Andrew R.|date=2019-03|title=Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups|url=https://www.nature.com/articles/s41586-019-1007-8|journal=Nature|language=en|volume=567|issue=7748|pages=399–404|doi=10.1038/s41586-019-1007-8|issn=1476-4687}}</ref><ref>{{Cite news|url=https://www.bbc.com/news/health-47553534|title=Cancer's 'internal wiring' predicts relapse risk|last=Gallagher|first=James|date=2019-03-14|access-date=2019-08-29|language=en-GB}}</ref><ref>{{Cite web|url=https://www.independent.co.uk/news/health/breast-cancer-test-return-risk-calculator-genetic-cambridge-study-a8821476.html|title=Breast cancer test could predict chances of disease’s return 20 years later, study shows|date=2019-03-13|website=The Independent|language=en|access-date=2019-08-29}}</ref>
Caldas' research focuses on the [[functional genomics]] of [[breast cancer]].<ref>{{Cite web|url=https://scholar.google.co.uk/citations?user=cWlqL14AAAAJ&hl=en|title=Carlos Caldas - Google Scholar Citations|website=scholar.google.co.uk|access-date=2019-08-29}}</ref><ref>{{Cite web|url=https://www.cruk.cam.ac.uk/research-groups/caldas-group|title=Caldas Group|website=Cancer Research UK Cambridge Institute|access-date=2019-08-29}}</ref> Caldas led the METABRIC (Molecular Taxonomy of Breast Cancer International Consortium) study, analysing the [[genome]] and [[transcriptome]] of tumours from nearly 2,000 women and comparing this with long-term clinical information including survival, age and diagnosis. The METABRIC study concluded that breast cancer was at least ten different subtypes, characterised by distinct genomic drivers.<ref>{{Cite journal|last=Aparicio|first=Samuel|last2=Caldas|first2=Carlos|last3=Tavaré|first3=Simon|last4=Brenton|first4=James D.|last5=Børresen-Dale|first5=Anne-Lise|last6=Purushotham|first6=Arnie|last7=Ellis|first7=Ian|last8=Murphy|first8=Leigh|last9=Markowetz|first9=Florian|date=June 2012|title=The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups|url=https://www.nature.com/articles/nature10983|journal=Nature|volume=486|issue=7403|pages=346–352|doi=10.1038/nature10983|issn=1476-4687}}</ref><ref>{{Cite journal|last=Curtis|first=C.|last2=Shah|first2=S.|last3=Chin|first3=S.|last4=Turashvili|first4=G.|last5=Rueda|first5=O.|last6=Dunning|first6=M.|last7=Speed|first7=D.|last8=Lynch|first8=A.|last9=Samarajiwa|first9=S.|date=2012|title=The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups|url=https://scienceblog.cancerresearchuk.org/2012/04/18/increasing-the-resolution-on-breast-cancer-the-metabric-study/|journal=Nature|doi=10.1038/nature10983|issn=0028-0836}}</ref><ref>{{Cite news|url=https://www.bbc.com/news/health-17740690|title=Breast cancer map 'a key moment'|last=Gallagher|first=James|date=2012-04-18|access-date=2019-08-29}}</ref> In 2019, the team published research showing the subtype a women's breast cancer is initially placed in could predict the likelyhood of the tumour returning or [[metastasis]]ing over the next 20 years.<ref>{{Cite journal|last=Curtis|first=Christina|last2=Caldas|first2=Carlos|last3=Aparicio|first3=Samuel|last4=Rueda|first4=Cristina|last5=Pharoah|first5=Paul D.|last6=Ellis|first6=Ian O.|last7=Purushotham|first7=Arnie|last8=Murphy|first8=Leigh|last9=Green|first9=Andrew R.|date=March 2019|title=Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups|url=https://www.nature.com/articles/s41586-019-1007-8|journal=Nature|volume=567|issue=7748|pages=399–404|doi=10.1038/s41586-019-1007-8|issn=1476-4687}}</ref><ref>{{Cite news|url=https://www.bbc.com/news/health-47553534|title=Cancer's 'internal wiring' predicts relapse risk|last=Gallagher|first=James|date=2019-03-14|access-date=2019-08-29}}</ref><ref>{{Cite web|url=https://www.independent.co.uk/news/health/breast-cancer-test-return-risk-calculator-genetic-cambridge-study-a8821476.html|title=Breast cancer test could predict chances of disease’s return 20 years later, study shows|date=2019-03-13|website=The Independent|access-date=2019-08-29}}</ref>


Professor Caldas leads the Personalised Breast Cancer Programme in Cambridge, where woman diagnosed with breast cancer have a sample of their tumour and blood sent for [[DNA sequencing|DNA]] and [[RNA sequencing]]. The sequencing results help determine the best course of treatment for patients and can reveal if their tumour is developing resistance to treatment.<ref>{{Cite news|url=https://www.bbc.com/news/health-44455354|title=DNA 'barcode' can transform cancer care|last=Walsh|first=Fergus|date=2018-06-27|access-date=2019-08-29|language=en-GB}}</ref><ref>{{Cite web|url=https://www.cambridge-news.co.uk/news/health/breast-cancer-dna-barcode-addenbookes-14942750|title=Breast cancer DNA ‘barcoding’ programme set to expand|last=Pilgrim|first=Tom|date=2018-07-23|website=cambridgenews|access-date=2019-08-29}}</ref><ref>{{Cite web|url=https://www.cuh.nhs.uk/news/breast-unit/pbcp-study-takes-breast-cancer-research-next-level-development-personalised-cancer-medicine|title=PBCP study takes breast cancer research to the next level in the development of personalised cancer medicine {{!}} Cambridge University Hospitals|website=www.cuh.nhs.uk|access-date=2019-08-29}}</ref>
Professor Caldas leads the Personalised Breast Cancer Programme in Cambridge, where woman diagnosed with breast cancer have a sample of their tumour and blood sent for [[DNA sequencing|DNA]] and [[RNA sequencing]]. The sequencing results help determine the best course of treatment for patients and can reveal if their tumour is developing resistance to treatment.<ref>{{Cite news|url=https://www.bbc.com/news/health-44455354|title=DNA 'barcode' can transform cancer care|last=Walsh|first=Fergus|date=2018-06-27|access-date=2019-08-29}}</ref><ref>{{Cite web|url=https://www.cambridge-news.co.uk/news/health/breast-cancer-dna-barcode-addenbookes-14942750|title=Breast cancer DNA ‘barcoding’ programme set to expand|last=Pilgrim|first=Tom|date=2018-07-23|website=cambridgenews|access-date=2019-08-29}}</ref><ref>{{Cite web|url=https://www.cuh.nhs.uk/news/breast-unit/pbcp-study-takes-breast-cancer-research-next-level-development-personalised-cancer-medicine|title=PBCP study takes breast cancer research to the next level in the development of personalised cancer medicine {{!}} Cambridge University Hospitals|website=www.cuh.nhs.uk|access-date=2019-08-29}}</ref>


== Awards and honours ==
== Awards and honours ==
Line 47: Line 49:
* [[Academy of Medical Sciences (United Kingdom)|Academy of Medical Sciences]] Fellow, 2004<ref>{{Cite web|url=https://acmedsci.ac.uk/fellows/fellows-directory/ordinary-fellows/fellow/Professor-Carlos-Caldas-0006182|title=Professor Carlos Caldas {{!}} The Academy of Medical Sciences|website=acmedsci.ac.uk|access-date=2019-08-29}}</ref>
* [[Academy of Medical Sciences (United Kingdom)|Academy of Medical Sciences]] Fellow, 2004<ref>{{Cite web|url=https://acmedsci.ac.uk/fellows/fellows-directory/ordinary-fellows/fellow/Professor-Carlos-Caldas-0006182|title=Professor Carlos Caldas {{!}} The Academy of Medical Sciences|website=acmedsci.ac.uk|access-date=2019-08-29}}</ref>
* European Academy of Cancer Sciences Fellow, 2010<ref>{{Cite web|url=https://www.europeancanceracademy.eu/content/directory.php|title=Fellows{{!}} European Academy of Cancer Sciences|website=www.europeancanceracademy.eu|access-date=2019-08-29}}</ref>
* European Academy of Cancer Sciences Fellow, 2010<ref>{{Cite web|url=https://www.europeancanceracademy.eu/content/directory.php|title=Fellows{{!}} European Academy of Cancer Sciences|website=www.europeancanceracademy.eu|access-date=2019-08-29}}</ref>
* [[European Molecular Biology Organization|EMBO]] member, 2015<ref>{{Cite web|url=https://people.embo.org/profile/carlos-caldas|title=Find people in the EMBO Communities|website=people.embo.org|access-date=2019-08-29}}</ref><ref>{{Cite web|url=https://www.cruk.cam.ac.uk/2015/05/20/three-cruk-ci-group-leaders-elected-to-embo-membership|title=Three Group Leaders elected to EMBO Membership|date=2015-05-20|website=Cancer Research UK Cambridge Institute|language=en-GB|access-date=2019-08-29}}</ref>
* [[European Molecular Biology Organization|EMBO]] member, 2015<ref>{{Cite web|url=https://people.embo.org/profile/carlos-caldas|title=Find people in the EMBO Communities|website=people.embo.org|access-date=2019-08-29}}</ref><ref>{{Cite web|url=https://www.cruk.cam.ac.uk/2015/05/20/three-cruk-ci-group-leaders-elected-to-embo-membership|title=Three Group Leaders elected to EMBO Membership|date=2015-05-20|website=Cancer Research UK Cambridge Institute|access-date=2019-08-29}}</ref>
* [[European Society for Medical Oncology]] Hamilton Fairley Award, 2016<ref>{{Cite web|url=https://www.esmo.org/Press-Office/ESMO-Recognises-Carlos-Caldas-with-Hamilton-Fairley-Award|title=Press Release: ESMO Recognises Carlos Caldas with Hamilton Fairley Award {{!}} ESMO|website=www.esmo.org|access-date=2019-08-29}}</ref>
* [[European Society for Medical Oncology]] Hamilton Fairley Award, 2016<ref>{{Cite web|url=https://www.esmo.org/Press-Office/ESMO-Recognises-Carlos-Caldas-with-Hamilton-Fairley-Award|title=Press Release: ESMO Recognises Carlos Caldas with Hamilton Fairley Award {{!}} ESMO|website=www.esmo.org|access-date=2019-08-29}}</ref>


Line 53: Line 55:


<references />
<references />



{{DEFAULTSORT:Caldas, Carlos}}
{{DEFAULTSORT:Caldas, Carlos}}

Revision as of 21:04, 2 September 2019

Carlos Caldas
FMedSci
Born
Carlos Manuel Simão da Silva Caldas

26 June 1960
Alma materUniversity of Lisbon Medical School
AwardsFellow of the Academy of Medical Sciences
Scientific career
InstitutionsCancer Research UK Cambridge Institute, University of Cambridge Addenbrooke's Hospital
Websitewww.cruk.cam.ac.uk/research-groups/caldas-group

Professor Carlos Caldas FMedSci is a clinician scientist and Senior Group Leader at the Cancer Research UK Cambridge Institute, University of Cambridge. He is the Chair of Cancer Medicine at the University of Cambridge, an Honorary Consultant Medical Oncologist at Addenbrooke's Hospital and Director of the Cambridge Breast Cancer Research Unit.[1][2]

Education

Professor Carlos Caldas graduated from the University of Lisbon Medical School before training in Internal Medicine in University of Texas Southwestern, Dallas and Medical Oncology at Johns Hopkins Hospital, Baltimore. He then moved to the Institute of Cancer Research, London to complete a research fellowship.[1]

Research and Career

Caldas' research focuses on the functional genomics of breast cancer.[3][4] Caldas led the METABRIC (Molecular Taxonomy of Breast Cancer International Consortium) study, analysing the genome and transcriptome of tumours from nearly 2,000 women and comparing this with long-term clinical information including survival, age and diagnosis. The METABRIC study concluded that breast cancer was at least ten different subtypes, characterised by distinct genomic drivers.[5][6][7] In 2019, the team published research showing the subtype a women's breast cancer is initially placed in could predict the likelyhood of the tumour returning or metastasising over the next 20 years.[8][9][10]

Professor Caldas leads the Personalised Breast Cancer Programme in Cambridge, where woman diagnosed with breast cancer have a sample of their tumour and blood sent for DNA and RNA sequencing. The sequencing results help determine the best course of treatment for patients and can reveal if their tumour is developing resistance to treatment.[11][12][13]

Awards and honours

References

  1. ^ a b "Prof C Caldas | Cambridge University Hospitals". www.cuh.nhs.uk. Retrieved 2019-08-29.
  2. ^ [email protected]. "Professor Carlos Caldas — Department of Oncology". www.oncology.cam.ac.uk. Retrieved 2019-08-29.{{cite web}}: CS1 maint: numeric names: authors list (link)
  3. ^ "Carlos Caldas - Google Scholar Citations". scholar.google.co.uk. Retrieved 2019-08-29.
  4. ^ "Caldas Group". Cancer Research UK Cambridge Institute. Retrieved 2019-08-29.
  5. ^ Aparicio, Samuel; Caldas, Carlos; Tavaré, Simon; Brenton, James D.; Børresen-Dale, Anne-Lise; Purushotham, Arnie; Ellis, Ian; Murphy, Leigh; Markowetz, Florian (June 2012). "The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups". Nature. 486 (7403): 346–352. doi:10.1038/nature10983. ISSN 1476-4687.
  6. ^ Curtis, C.; Shah, S.; Chin, S.; Turashvili, G.; Rueda, O.; Dunning, M.; Speed, D.; Lynch, A.; Samarajiwa, S. (2012). "The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups". Nature. doi:10.1038/nature10983. ISSN 0028-0836.
  7. ^ Gallagher, James (2012-04-18). "Breast cancer map 'a key moment'". Retrieved 2019-08-29.
  8. ^ Curtis, Christina; Caldas, Carlos; Aparicio, Samuel; Rueda, Cristina; Pharoah, Paul D.; Ellis, Ian O.; Purushotham, Arnie; Murphy, Leigh; Green, Andrew R. (March 2019). "Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups". Nature. 567 (7748): 399–404. doi:10.1038/s41586-019-1007-8. ISSN 1476-4687.
  9. ^ Gallagher, James (2019-03-14). "Cancer's 'internal wiring' predicts relapse risk". Retrieved 2019-08-29.
  10. ^ "Breast cancer test could predict chances of disease's return 20 years later, study shows". The Independent. 2019-03-13. Retrieved 2019-08-29.
  11. ^ Walsh, Fergus (2018-06-27). "DNA 'barcode' can transform cancer care". Retrieved 2019-08-29.
  12. ^ Pilgrim, Tom (2018-07-23). "Breast cancer DNA 'barcoding' programme set to expand". cambridgenews. Retrieved 2019-08-29.
  13. ^ "PBCP study takes breast cancer research to the next level in the development of personalised cancer medicine | Cambridge University Hospitals". www.cuh.nhs.uk. Retrieved 2019-08-29.
  14. ^ "Professor Carlos Caldas | The Academy of Medical Sciences". acmedsci.ac.uk. Retrieved 2019-08-29.
  15. ^ "Fellows| European Academy of Cancer Sciences". www.europeancanceracademy.eu. Retrieved 2019-08-29.
  16. ^ "Find people in the EMBO Communities". people.embo.org. Retrieved 2019-08-29.
  17. ^ "Three Group Leaders elected to EMBO Membership". Cancer Research UK Cambridge Institute. 2015-05-20. Retrieved 2019-08-29.
  18. ^ "Press Release: ESMO Recognises Carlos Caldas with Hamilton Fairley Award | ESMO". www.esmo.org. Retrieved 2019-08-29.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Carlos_Caldas&oldid=913727265"